Back to top
more

NOVAN INC (NOVN)

(Delayed Data from NSDQ)

$1.22 USD

1.22
446,147

+0.07 (5.75%)

Updated May 3, 2019 03:59 PM ET

After-Market: $1.22 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[NOVN]

Reports for Purchase

Showing records 1 - 20 ( 100 total )

Industry: Medical - Drugs

Record: 1

07/18/2023

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

06/01/2023

Daily Note

Pages: 12

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

06/01/2023

Company Report

Pages: 5

Exploring Marketed Drugs Sale, Focusing on SB206, 50% RIF (Mostly Sales)

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

05/15/2023

Daily Note

Pages: 7

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

05/15/2023

Company Report

Pages: 6

1Q23: Temporary Fade in RHOFADE Sales Fixed, SB206 Likely Approved Jan ''24

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

04/26/2023

Company Report

Pages: 5

KOL Call Highlights That Likely Favorable Market Dynamics Await KINSOLUS

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

04/26/2023

Daily Note

Pages: 5

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

03/30/2023

Company Report

Pages: 6

4Q22: Strong 4Q22 Prescription Growth, Expecting 1Q24 KINSOLUS Approval

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

01/06/2023

Company Report

Pages: 8

SB206 (KINSOLUS) Long-Awaited NDA for Molluscum Filed; Project 1Q24 Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

12/22/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

12/21/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

12/21/2022

Company Report

Pages: 5

Sato Licenses RHOFADE Development and Commercial Rights In Japan

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

11/18/2022

Company Report

Pages: 6

3Q22: Expect SB206 NDA Filing by January; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

11/14/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

11/14/2022

Company Report

Pages: 6

3Q22: Expected Seasonal Product Rev Drop, Kinsolus NDA Filing Around YE22

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

10/24/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

10/21/2022

Company Report

Pages: 6

Survey Shows Patients Value Attributes Like Those Possessed By Wynzora

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

08/16/2022

Company Report

Pages: 9

2Q22: Recently Acquired Commercial Business Pays for Itself While SB206 On Track for Year-End NDA Filing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

08/12/2022

Company Report

Pages: 9

2Q22: Recently Acquired Commercial Business Pays for Itself While SB206 On Track for end-2023 NDA Filing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

08/11/2022

Company Report

Pages: 5

2Q22: Growth in Promoted Product Sales, Kinsolus NDA Expected By YE22

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party
// eof